PepGen Inc.

What they do

PepGen uses its Enhanced Delivery Oligonucleotide (EDO) platform, based on cell-penetrating peptides, to develop therapies for severe neuromuscular and neurologic diseases. Its lead candidate, PGN-EDODM1, is designed to bind to the pathogenic CUG repeat in DMPK mRNA to correct mis-splicing in DM1 patients. The company is currently running Phase 1 (FREEDOM, completed), Phase 2 (FREEDOM2), and an open-label extension (FREEDOM-OLE) studies for PGN-EDODM1.

Revenue drivers

• No approved products or revenue — The company has no commercial products and has not generated any revenue from product sales; it is entirely dependent on the success of PGN-EDODM1 and future candidates.
• PGN-EDODM1 (DM1 program) — The sole product candidate; potential revenue would come from treating DM1, a disease with no approved therapies, but clinical development is ongoing and regulatory approval is uncertain.
• Future pipeline expansion — Management intends to expand the EDO platform to other severe diseases, but no specific candidates or timelines have been disclosed.

Recent performance

For Q2 2026, PepGen reported a net loss of $17.8 million, or $(0.26) per share, compared to a $23.1 million loss, or $(0.70) per share, in Q2 2025. R&D expenses decreased to $12.5 million from $18.4 million, while G&A expenses increased to $6.4 million from $5.5 million. Cash and marketable securities were $117.2 million as of June 30, 2026. The FREEDOM2 10 mg/kg cohort is fully enrolled with 7 of 8 patients dosed, and the DSMB recommended dose escalation to 12.5 mg/kg.

Strategy

The strategy is to advance PGN-EDODM1 through Phase 2, with plans to report 10 mg/kg data in November 2026 and 12.5 mg/kg data in 1H 2027, then engage in an end-of-Phase 2 meeting with regulators. The company is also dose-escalating the open-label extension to 10 mg/kg and aims to build on the splicing correction seen in Phase 1. Management plans to expand the EDO platform beyond DM1 to other severe diseases. The company is also working to resolve the FDA partial clinical hold on the U.S. FREEDOM2 study by submitting additional analyses.

Risks

• Dependence on single candidate — PepGen has no approved products and is substantially dependent on PGN-EDODM1; failure to develop or obtain approval would harm the business.
• FDA partial clinical hold — The FREEDOM2 study is on partial clinical hold in the U.S. due to FDA questions about preclinical studies, which could delay U.S. enrollment.
• Clinical trial uncertainty — Data from the FREEDOM2 5 mg/kg cohort showed no meaningful improvement over placebo in splicing when including an outlier patient; efficacy results in later cohorts may not support registration.
• Limited cash runway — Cash of $117.2 million is expected to fund operations only into Q4 2027, requiring additional capital to complete development and potentially diluting shareholders.

Outlook

Management expects to report 10 mg/kg cohort data in November 2026 and 12.5 mg/kg data in the first half of 2027, with an OLE update by early January. They plan to initiate enrollment in the 12.5 mg/kg cohort shortly and, pending results, hold an end-of-Phase 2 meeting to discuss the registrational program. The company believes its cash is sufficient to fund operations into the fourth quarter of 2027.